Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Myeloid Therapeutics
Incyte Corporation
Novartis
Nurix Therapeutics, Inc.
Xencor, Inc.
Lyell Immunopharma, Inc.
Dana-Farber Cancer Institute
Theratechnologies
University of Washington
Exelixis
Carisma Therapeutics Inc
Light Chain Bioscience - Novimmune SA
Eli Lilly and Company
BioEclipse Therapeutics
Multitude Therapeutics Inc.
Canadian Cancer Trials Group
Xencor, Inc.
MacroGenics
AIDS Malignancy Consortium
Abramson Cancer Center at Penn Medicine
University of Washington
Pfizer
Albert Einstein College of Medicine
University of Chicago
Wake Forest University Health Sciences
University of Washington
University of Louisville
University of Southern California
University of Arizona
City of Hope Medical Center
University of Washington
Indiana University
University of California, San Francisco
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)